Sp1117
MICROBIOME IN GASTROINTESTINAL DISEASES
Date
May 9, 2023
Explore related products in the following collection:
Society: AGA
Experts in different fields across Latin American review and highlight selected abstracts presented at Digestive Disease Week® (DDW) 2023 in Spanish.
Experts in different fields across Latin American review and highlight selected abstracts presented at Digestive Disease Week® (DDW) 2023 in Spanish.
Presenter
Tracks
Related Products
IS THE SARS-COV-2 VIRUS A TRIGGER AGENT FOR THE DEVELOPMENT OF ACHALASIA?
Dysphagia and chest pain are the common symptoms in achalasia. The mechanisms underlying such symptoms are not completely understood. The two symptoms can be triggered by mechanical stimulation via the sensory vagal and spinal afferent nerve fibers…
PLACEHOLDER
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMIS-UC, COHORT 1
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
PLACEHOLDER
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…
